Skip to main content
SpringerLink
Log in

Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings

  • Chapter
  • First Online:
Breast Cancer

  • 123k Accesses

Abstract

In both early and advanced breast cancer, chemotherapy forms a vital component of most treatment algorithms, despite the arrival of targeted agents. The number of agents with meaningful activity is large, particularly in advanced disease, and the choice of regimen must take into account predicted efficacy and toxicity in the context of prognostic factors and patient wishes. Several chemotherapy regimens may exist for a given clinical situation, and selecting an optimal treatment can be difficult, despite progress in the understanding of molecular subtypes and relevant mutations. In early-stage disease, the superiority of one regimen over another must be considered in the context of the absolute risk of relapse. Additionally, luminal subtypes may have lower overall chemosensitivity, which can influence choice. In advanced disease, tolerability plays a greater role. The use of tumour subtype or genomic markers such as BRCA mutation to assist in selecting optimal agents is promising but remains investigational. This chapter will consider the range of chemotherapy options available and offer evidence-based suggestions for current management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AC:

Doxorubicin plus cyclophosphamide, 4 cycles given 3 weekly (2 weekly for dose-dense) (×4, q21 or q14)

CMF:

Cyclophosphamide, methotrexate, fluorouracil, ×6 q28 (d1+d8)

FEC:

Fluorouracil, epirubicin, cyclophosphamide, ×6 q21

EC:

Epirubicin cyclophosphamide

(F)EC-D:

Epirubicin plus cyclophosphamide (with or without fluorouracil) ×3 followed by docetaxel ×3, q21 (or q14 for dose-dense)

TC:

Docetaxel cyclophosphamide ×4 q21

TCH:

Docetaxel cyclophosphamide trastuzumab ×4 q21, trastuzumab continued for total 1 year

TCarboH:

Docetaxel carboplatin trastuzumab ×6 q21, trastuzumab continued for total 1 year

References

  1. Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330(7485):217

    Article  PubMed  PubMed Central  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. doi:10.1016/S0140-6736(11)61625-5. Epub 2011 Dec 5

    Article  Google Scholar 

  3. Berry DA, Ueno NT, Johnson MM et al (2011) High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29(24):3214–3223. doi:10.1200/JCO.2010.32.5910. Epub 2011 Jul 18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8(9):1483–1496

    Article  CAS  PubMed  Google Scholar 

  5. Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19(4):931–942

    Article  CAS  PubMed  Google Scholar 

  6. Jones S, Holmes F, O’Shaughnessey J et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research trial 9735. J Clin Oncol 27:1177–1183

    Article  CAS  PubMed  Google Scholar 

  7. Shulman LN, Berry DA, Cirrincione CT et al (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32(22):2311–2317. doi:10.1200/JCO.2013.53.7142. Epub 2014 Jun 16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Del Mastro L, De Placido S, Bruzzi P et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872. doi:10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2

    Article  PubMed  Google Scholar 

  9. Roche H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 001 trial. J Clin Oncol 24:5664–5671

    Article  CAS  PubMed  Google Scholar 

  10. Samuel JA, Wilson JW, Bandos H et al. [S3-02] NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. Presented at 2014 San Antonio Breast Cancer Symposium, December 11, 2014, San Antonio, Texas

    Google Scholar 

  11. Bonilla L, Ben-Aharon I, Vidal L et al (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102(24):1845–1854. doi:10.1093/jnci/djq409. Epub 2010 Nov 23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439. Epub 2003 Feb 13

    Article  CAS  PubMed  Google Scholar 

  13. Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in adjuvant treatment of breast cancer. N Engl J Med 258:1663–1671

    Article  Google Scholar 

  14. Bear HD, Tang G, Rastogi P et al (2015) Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 16(9):1037–1048. doi:10.1016/S1470-2045(15)00041-8. Epub 2015 Aug 10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sonnenblick A, Francis PA, Azim HA Jr et al (2015) Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer 51(12):1481–1489. doi:10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11

    Article  CAS  PubMed  Google Scholar 

  16. Hart CD, Sanna G, Siclari O et al (2015) Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. Breast 24(Suppl 2):S136–S142. doi:10.1016/j.breast.2015.07.033. Epub 2015 Aug 29

    Article  PubMed  Google Scholar 

  17. Xu C, Wei Q, Guo J et al (2015) FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients. Ann Surg Oncol 22(6):2034–2039. doi:10.1245/s10434-014-4313-2. Epub 2015 Feb 24

    Article  PubMed  Google Scholar 

  18. Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8–30. doi:10.1093/annonc/mdv298

    Article  PubMed  Google Scholar 

  19. Sparano JA, Gray RJ, Makower DF et al (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373(21):2005–2014. doi:10.1056/NEJMoa1510764. Epub 2015 Sep 27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Goss PE, Smith IE, O'Shaughnessy J et al (2013) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14(1):88–96. doi:10.1016/S1470-2045(12)70508-9. Epub 2012 Dec 10

    Article  CAS  PubMed  Google Scholar 

  21. Piccart-Gebhart M, Holmes E, Baselga J et al (2015) Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol. pii: JCO621797 [Epub ahead of print]

    Google Scholar 

  22. Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32. doi:10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6

    Article  CAS  PubMed  Google Scholar 

  23. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028. doi:10.1016/S0140-6736(13)61094-6. Epub 2013 Jul 18

    Article  CAS  PubMed  Google Scholar 

  24. Pivot X, Romieu G, Debled M et al (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741–748. doi:10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11

    Article  CAS  PubMed  Google Scholar 

  25. Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141. doi:10.1056/NEJMoa1406281

    Article  PubMed  PubMed Central  Google Scholar 

  26. Advani PP, Ballman KV, Dockter TJ et al (2016) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 34(6):581–587. doi:10.1200/JCO.2015.61.8413. Epub 2015 Sep 21

    Article  CAS  PubMed  Google Scholar 

  27. Slamon DJ, Eiermann W, Robert NJ et al. [S5-04] Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Presented at 2015 San Antonio Breast Cancer Symposium, December 11, 2015, San Antonio, Texas

    Google Scholar 

  28. Telli ML, Jensen KC, Vinayak S et al (2015) Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol 33(17):1895–1901. doi:10.1200/JCO.2014.57.0085. Epub 2015 Apr 6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Byrski T, Huzarski T, Dent R et al (2014) Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147(2):401–405. doi:10.1007/s10549-014-3100-x. Epub 2014 Aug 17

    Article  CAS  PubMed  Google Scholar 

  30. von Minckwitz G, Loibl S, Schneeweiss A et al. [S2-04] Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Presented at 2015 San Antonio Breast Cancer Symposium, December 9, 2015, San Antonio, Texas

    Google Scholar 

  31. Cardoso F, Costa A, Norton L et al (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25(10):1871–1888. doi:10.1093/annonc/mdu385. Epub 2014 Sep 18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Partridge AH, Rumble RB, Carey LA et al (2014) Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(29):3307–3329. doi:10.1200/JCO.2014.56.7479. Epub 2014 Sep 2

    Article  PubMed  Google Scholar 

  33. NCCC: National Collaborating Centre for Cancer (UK). Advanced Breast Cancer: Diagnosis and Treatment. Cardiff (UK): National Collaborating Centre for Cancer (UK); 2009.

    Google Scholar 

  34. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676

    Article  CAS  PubMed  Google Scholar 

  35. Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286–4293. doi:10.1200/JCO.2010.34.1255. Epub 2011 Oct 11

    Article  CAS  PubMed  Google Scholar 

  36. Gennari A, Stockler M, Puntoni M et al (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29(16):2144–2149. doi:10.1200/JCO.2010.31.5374. Epub 2011 Apr 4

    Article  PubMed  Google Scholar 

  37. Oshaughnessy JA, Blum J, Moiseyenko V et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9):1247–1254

    Article  CAS  PubMed  Google Scholar 

  38. Aapro M, Finek J (2012) Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev 38(2):120–126. doi:10.1016/j.ctrv.2011.05.005. Epub 2011 Jul 13

    Article  CAS  PubMed  Google Scholar 

  39. Weber BL, Vogel C, Jones S et al (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13(11):2722–2730

    Article  CAS  PubMed  Google Scholar 

  40. Cortes J, O'Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914–923. doi:10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2

    Article  CAS  PubMed  Google Scholar 

  41. Kaufman PA, Awada A, Twelves C et al (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594–601. doi:10.1200/JCO.2013.52.4892. Epub 2015 Jan 20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Twelves C, Cortes J, Vahdat L et al (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148(3):553–561. doi:10.1007/s10549-014-3144-y. Epub 2014 Nov 8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Tutt A, Ellis P, Kilbum L, et al. TNT: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast cancer. San Antonio Breast Cancer Symposium 2014

    Google Scholar 

  44. Vollebergh MA, Lips EH, Nederlof PM et al (2014) Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res 16(3):R47. doi:10.1186/bcr3655

    Article  PubMed  PubMed Central  Google Scholar 

  45. Stockler MR, Harvey VJ, Francis PA et al (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504. doi:10.1200/JCO.2010.33.9101. Epub 2011 Oct 24

    Article  CAS  PubMed  Google Scholar 

  46. Campone M, Dobrovolskaya N, Tjulandin S et al (2013) A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast J 19(3):240–249. doi:10.1111/tbj.12098. Epub 2013 Mar 26

    Article  CAS  PubMed  Google Scholar 

  47. Nolè F, Crivellari D, Mattioli R et al (2009) Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64(4):673–680. doi:10.1007/s00280-008-0915-3. Epub 2009 Jan 31

    Article  PubMed  Google Scholar 

  48. Yardley DA, Brufsky A, Coleman RE et al (2015) Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 16(1):575. doi:10.1186/s13063-015-1101-7

    Article  PubMed  PubMed Central  Google Scholar 

  49. Wang Z, Lu J, Leaw S et al (2012) An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 69(2):515–522. doi:10.1007/s00280-011-1728-3. Epub 2011 Aug 27

    Article  CAS  PubMed  Google Scholar 

  50. Yoshimoto M, Takao S, Hirata M et al (2012) Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol 70(2):331–338. doi:10.1007/s00280-012-1826-x. Epub 2012 Apr 11

    Article  CAS  PubMed  Google Scholar 

  51. Schwartzberg LS, Wang G, Somer BG et al (2014) Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Breast Cancer 14(1):13–19. doi:10.1016/j.clbc.2013.09.003. Epub 2013 Sep 27

    Article  CAS  PubMed  Google Scholar 

  52. Orlando L, Cardillo A, Rocca A et al (2006) Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs 17(8):961–967

    Article  CAS  PubMed  Google Scholar 

  53. Swain SM, Baselga J, Kim SB et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734. doi:10.1056/NEJMoa1413513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791. doi:10.1056/NEJMoa1209124. Epub 2012 Oct 1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Wildiers H, Kim S-B, Gonzalez-Martin A, et al. [S5-05] Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study Presented at 2015 San Antonio Breast Cancer Symposium, December 11, 2015, San Antonio, Texas

    Google Scholar 

  56. Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29(3):264–271. doi:10.1200/JCO.2010.30.8213. Epub 2010 Dec 13

    Article  CAS  PubMed  Google Scholar 

  57. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743

    Article  CAS  PubMed  Google Scholar 

  58. Cameron D, Casey M, Oliva C et al (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15(9):924–934. doi:10.1634/theoncologist.2009-0181. Epub 2010 Aug 24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Gelmon KA, Boyle FM, Kaufman B et al (2015) Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol 33(14):1574–1583. doi:10.1200/JCO.2014.56.9590. Epub 2015 Mar 16

    Article  CAS  PubMed  Google Scholar 

  60. Blackwell KL, Burstein HJ, Storniolo AM et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30(21):2585–2592. doi:10.1200/JCO.2011.35.6725. Epub 2012 Jun 11

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sandro Pitigliani Department of Medical Oncology, Istituto Toscano Tumori, Prato, Italy

    Christopher D. Hart, Laura Biganzoli & Angelo Di Leo

Authors
  1. Christopher D. Hart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Biganzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angelo Di Leo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Di Leo .

Editor information

Editors and Affiliations

  1. European Institutee of Oncology, Milan, Italy

    Umberto Veronesi

  2. European Institute of Oncology, Milan, Italy

    Aron Goldhirsch

  3. European Institute of Oncology, Milan, Italy

    Paolo Veronesi

  4. San Raffaele University and Research Hospital, Milano, Italy

    Oreste Davide Gentilini

  5. European Institute of Oncology, Milan, Italy

    Maria Cristina Leonardi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hart, C.D., Biganzoli, L., Di Leo, A. (2017). Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings. In: Veronesi, U., Goldhirsch, A., Veronesi, P., Gentilini, O., Leonardi, M. (eds) Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-48848-6_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-48848-6_46

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-48846-2

  • Online ISBN: 978-3-319-48848-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation